Answers are grounded in this paper and cite their sources.
The highly porous and robust [Ni(8)(OH)(4)(OH(2))(2)(4,4'-(buta-1,3-diyne-1,4-diyl)bispyrazolato)(6)](n) MOF can be used as a proof of concept for the incorporation and release of the non-conventional [Ru(p-cymene)Cl(2)(pta)] RAPTA-C metallodrug.
No takes yet. Share an insight, caveat, or question.
Procopio et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: